Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients

Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs, without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our pre-clinical results suggested that combined MCT with cyclophosphamide (CY)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Perroud, Herman A, Rico, María José, Alasino, Carlos María, Queralt, Francisco , Mainetti, Leandro Ernesto, Pezzotto, Stella Maris, Rozados, Viviana R., Scharovsky, O. Graciela
Formato: article artículo acceptedVersion
Lenguaje:Inglés
Publicado: Future Medicine Ltd 2018
Materias:
Breast cancer
Biomarkers
Metronomic chemotherapy
Cyclophosphamide
Celecoxib
Acceso en línea:http://hdl.handle.net/2133/11302
http://hdl.handle.net/2133/11302
Aporte de:
Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR) de Universidad Nacional de Rosario
id I15-R121-2133-11302
record_format dspace
institution Universidad Nacional de Rosario
institution_str I-15
repository_str R-121
collection Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR)
language Inglés
orig_language_str_mv eng
topic Breast cancer
Biomarkers
Metronomic chemotherapy
Cyclophosphamide
Celecoxib
spellingShingle Breast cancer
Biomarkers
Metronomic chemotherapy
Cyclophosphamide
Celecoxib
Perroud, Herman A
Rico, María José
Alasino, Carlos María
Queralt, Francisco 
Mainetti, Leandro Ernesto
Pezzotto, Stella Maris
Rozados, Viviana R.
Scharovsky, O. Graciela
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
topic_facet Breast cancer
Biomarkers
Metronomic chemotherapy
Cyclophosphamide
Celecoxib
description Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs, without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our pre-clinical results suggested that combined MCT with cyclophosphamide (CY) and celecoxib (CEL) could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of the oral chronic administration of CY 50 mg p.o. daily, plus CEL 400 mg (200 mg p.o. bid) in advanced breast cancer patients (ABCP). The therapeutic response consisted in stable disease in a high proportion of patients and one partial response. The overall clinical benefit rate obtained was 66.7%. Toxicity was low. Evaluation of quality of life showed no changes during the response period. MCT with CY + Cel is safe and shows therapeutic effect in ABCP.
format article
artículo
acceptedVersion
author Perroud, Herman A
Rico, María José
Alasino, Carlos María
Queralt, Francisco 
Mainetti, Leandro Ernesto
Pezzotto, Stella Maris
Rozados, Viviana R.
Scharovsky, O. Graciela
author_facet Perroud, Herman A
Rico, María José
Alasino, Carlos María
Queralt, Francisco 
Mainetti, Leandro Ernesto
Pezzotto, Stella Maris
Rozados, Viviana R.
Scharovsky, O. Graciela
author_sort Perroud, Herman A
title Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_short Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_full Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_fullStr Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_full_unstemmed Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
title_sort safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
publisher Future Medicine Ltd
publishDate 2018
url http://hdl.handle.net/2133/11302
http://hdl.handle.net/2133/11302
work_keys_str_mv AT perroudhermana safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
AT ricomariajose safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
AT alasinocarlosmaria safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
AT queraltfrancisco safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
AT mainettileandroernesto safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
AT pezzottostellamaris safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
AT rozadosvivianar safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
AT scharovskyograciela safetyandtherapeuticeffectofmetronomicchemotherapywithcyclophosphamideandcelecoxibinadvancedbreastcancerpatients
bdutipo_str Repositorios
_version_ 1764820408789368834

Ejemplares similares